Upadacitinib: the JAK inhibitor that achieved what other drugs could not.

We present an interesting case of severe ulcerative colitis flare, of challenging management because of a cytomegalovirus co-infection, in which upadacitinib achieved clinical and biochemical remission after poor responses to ganciclovir and tofacitinib.

Computational Insights into Membrane Disruption by Cell-Penetrating Peptides.

Cell-penetrating peptides (CPPs) can translocate into cells without inducing cytotoxicity. The internalization process implies several steps at different time scales ranging from microseconds to minutes. We combine adaptive Steered Molecular Dynamics (aSMD) with conventional Molecular Dynamics (cMD) to observe nonequilibrium and equilibrium states to study the early mechanisms of peptide-bilayer interaction leading to CPPs internalization.

Measurement distance effects on [Formula: see text]-symmetric Taylor patterns with optimal transition integer [Formula: see text] and with reduced inner sidelobes.

The following paper presents the findings of a study conducted on the distances at which the field generated by a ϕ-symmetric circular Taylor aperture distribution can be classified as far-field, and also the efficiency across various study parameters. The [Formula: see text] transition integers that produce a monotonic distribution, which have been traditionally used and analyzed, are compared with those that yield a peaked distribution, and offer greater efficiency. Additionally, modified circular Taylor [Formula: see text] distributions featuring synthesized patterns with one or two depressed inner sidelobes, which have not been previously explored, are also examined.

Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study).

Introduction: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario.

Methods: Retrospective multicenter study of patients with IBD who received upadacitinib before 31st December 2022 and at least 12 weeks before the recruitment date.